{
    "nct_id": "NCT05386758",
    "official_title": "An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of Molnupiravir (MK-4482; MOV) in Participants With Severe Renal Impairment",
    "inclusion_criteria": "The key Inclusion Criteria include but are not limited to the following:\n\n* Body mass index (BMI) ≥18.5 kg/m^2 and ≤35 kg/m^2\n* Healthy participants: Baseline estimated glomerular filtration rate (eGFR) ≥90 mL/min based on the 2021 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Creatinine equation\n* Severe renal impairment participants: Baseline estimated glomerular filtration rate (eGFR) <30 mL/min based on the 2021 CKD-EPI Creatinine equation\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 75 Years",
    "exclusion_criteria": "The key Exclusion Criteria include but are not limited to the following:\n\n* Positive for hepatitis B surface antigen (HBsAg), hepatitis C antibodies or human immunodeficiency virus (HIV)\n* History of major surgery, donated or lost 1 unit of blood (approximately 500 mL) within 4 weeks prior to the prestudy (screening) visit\n\nSevere renal impairment participants:\n\n* History or presence of renal artery stenosis\n* Had a renal transplant\n* Currently taking medications to treat chronic medical conditions associated with renal disease if participant has not been on a stable regimen for at least 1 month and/or is unable to withhold the use of medication(s) within 4 hours prior to and 8 hours after administration of the study drug",
    "miscellaneous_criteria": ""
}